Publikation

Treatment with Biologicals in Rheumatoid Arthritis: An Overview

Wissenschaftlicher Artikel/Review - 22.08.2017

Bereiche
PubMed
DOI

Zitation
Rein P, Müller R. Treatment with Biologicals in Rheumatoid Arthritis: An Overview. Rheumatol Ther 2017; 4:247-261.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Rheumatol Ther 2017; 4
Veröffentlichungsdatum
22.08.2017
ISSN (Druck)
2198-6576
Seiten
247-261
Kurzbeschreibung/Zielsetzung

Management and therapy of rheumatoid arthritis (RA) has been revolutionized by the development and approval of the first biological disease-modifying antirheumatic drugs (bDMARDs) targeting tumor necrosis factor (TNF) α at the end of the last century. Today, numerous efficacious agents with different modes of action are available and achievement of clinical remission or, at least, low disease activity is the target of therapy. Early therapeutic interventions aiming at a defined goal of therapy (treat to target) are supposed to halt inflammation, improving symptoms and signs, and preserving structural integrity of the joints in RA. Up to now, bDMARDs approved for therapy in RA include agents with five different modes of action: TNF inhibition, T cell co-stimulation blockade, IL-6 receptor inhibition, B cell depletion, and interleukin 1 inhibition. Furthermore, targeted synthetic DMARDs (tsDMARDs) inhibiting Janus kinase (JAK) and biosimilars also are approved for RA. The present review focuses on bDMARDs and tsDMARDS regarding similarities and possible drug-specific advantages in the treatment of RA. Furthermore, compounds not yet approved in RA and biosimilars are discussed. Following the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) recommendations, specific treatment of the disease will be discussed with respect to safety and efficacy. In particular, we discuss the question of favoring specific bDMARDs or tsDMARDs in the two settings of insufficient response to methotrexate and to the first bDMARD, respectively.